GoodRx, LifeMD gain on offerings for Novo’s Wegovy pill
Seeking Alpha News (Mon, 5-Jan 8:48 AM ET)
GoodRx, LifeMD gains on offerings for Novo’s Wegovy pill
Seeking Alpha News (Mon, 5-Jan 8:48 AM ET)
GoodRx Now Offers Novo Nordisk's Cash Price for the Launch of the Wegovy Pill
Business Wire (Mon, 5-Jan 8:05 AM ET)
Bank of America Securities Remains a Sell on GoodRx Holdings (GDRX)
TipRanks (Mon, 5-Jan 6:37 AM ET)
GoodRx to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Business Wire (Tue, 16-Dec 4:05 PM ET)
Business Wire (Mon, 17-Nov 8:35 AM ET)
GoodRx Reports Third Quarter 2025 Results
Business Wire (Tue, 4-Nov 4:05 PM ET)
GoodRx Launches New Hair Loss Subscription for Men to Simplify Access to Affordable Treatment
Business Wire (Wed, 15-Oct 9:00 AM ET)
GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call
Business Wire (Wed, 8-Oct 4:05 PM ET)
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Goodrx Holdings - Class A trades on the NASDAQ stock market under the symbol GDRX.
As of January 7, 2026, GDRX stock price declined to $2.89 with 708,950 million shares trading.
GDRX has a beta of 0.83, meaning it tends to be less sensitive to market movements. GDRX has a correlation of 0.07 to the broad based SPY ETF.
GDRX has a market cap of $1.04 billion. This is considered a Small Cap stock.
Last quarter Goodrx Holdings - Class A reported $196 million in Revenue and $.08 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.01.
In the last 3 years, GDRX traded as high as $9.37 and as low as $2.61.
The top ETF exchange traded funds that GDRX belongs to (by Net Assets): VTI, VB, VBR, VXF, CALF.
GDRX has underperformed the market in the last year with a return of -36.3%, while the SPY ETF gained +17.5%. In the last 3 month period, GDRX fell short of the market, returning -36.9%, while SPY returned +3.4%. However, in the most recent 2 weeks GDRX has outperformed the stock market by returning +5.1%, while SPY returned +0.7%.
GDRX support price is $2.83 and resistance is $2.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GDRX shares will trade within this expected range on the day.